Compare BDL & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDL | TENX |
|---|---|---|
| Founded | 1959 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 74.1M |
| IPO Year | 1995 | 2001 |
| Metric | BDL | TENX |
|---|---|---|
| Price | $66.40 | $1.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 50.7K | ★ 1.9M |
| Earning Date | 12-18-2026 | 11-16-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $205,248,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.55 | $1.31 |
| 52 Week High | $60.97 | $19.40 |
| Indicator | BDL | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 85.13 | 44.86 |
| Support Level | $29.23 | $1.34 |
| Resistance Level | N/A | $2.00 |
| Average True Range (ATR) | 2.80 | 0.13 |
| MACD | 1.66 | 0.08 |
| Stochastic Oscillator | 93.91 | 67.69 |
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.